Tolvaptan in a pediatric patient with diuretic-resistant heart and kidney failure

Area of Science:

• Pediatric Cardiology
• Nephrology
• Pharmacology

Background:

• Conventional diuretic therapy often fails to resolve volume overload in decompensated heart failure (CHF).
• Worsening kidney function in CHF patients complicates diuretic response and increases mortality risk.
• Diuretic resistance is a significant clinical challenge in managing pediatric CHF, especially with coexisting chronic kidney disease (CKD).

Observation:

• A 10-year-old boy with CHF and advanced CKD presented with persistent edema and oliguria despite escalating furosemide and spironolactone doses.
• The patient developed resistance to conventional diuretics, indicating a need for alternative treatment strategies.
• Tolvaptan was initiated, leading to improved sodium levels and effective decongestion.

Findings:

• Tolvaptan administration resulted in a gradual increase in plasma sodium levels.
• The patient achieved adequate decongestion, resolving the volume overload state.
• Cardiac function showed improvement following tolvaptan treatment.

Implications:

• Tolvaptan represents a potential therapeutic option for pediatric patients with diuretic-resistant CHF, even when complicated by advanced CKD.
• This case highlights the importance of considering novel pharmacological agents for refractory volume management in pediatric heart failure.
• Further research into tolvaptan's efficacy and safety in pediatric populations with complex comorbidities is warranted.